Prophylactic Ivermectin in COVID-19 Contacts

Phase 2

Completed

• Conditions: COVID
• Interventions: Drug: Ivermectin Tablets

• Registration Number: NCT04422561
• Lead Sponsor: Zagazig University

Brief Summary

asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms \& diagnosis of COVID -19

Detailed Description

Not available

Study Timeline

• Study Start: 2020-05-31
• Study First Submitted: 2020-06-06
• Study First Submitted QC: 2020-06-06
• Study First Posted: 2020-06-09
• Primary Completion: 2020-07-14
• Study Completion: 2020-07-27
• Status Verified: 2020-08
• Results First Submitted: 2020-08-23
• Results First Submitted QC: 2020-08-23
• Last Update Submitted: 2020-08-23
• Results First Posted: 2020-08-27
• Last Update Posted: 2020-08-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 340

Inclusion Criteria

family contact of confirmed COVID-19 case

Exclusion Criteria

• refuse to participate and receive the drug pregnancy or lactation known hypersensitivity to ivermectin

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Ivermectin group	Ivermectin Tablets	Contacts who will receive prophylactic ivermectin

Primary Outcome Measures

Name	Time	Method
Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)	within 14 days after enrollement	history taking and clinical examination

Secondary Outcome Measures

Name	Time	Method
Development of COVID	within 14 days after enrollement	by swab

Trial Locations

Locations (1)

Zagazig University; 🇪🇬 Zagazig, Sharkia, Egypt